Patent on methods of administering gamma-hydroxybutyrate compositions with divalproex sodium
The United States Patent Application US20240024263 focuses on methods of administering gamma-hydroxybutyrate (GHB) in combination with divalproex sodium (DVP), particularly for treating conditions like narcolepsy. The aim is to co-administer these drugs without altering their dosage or efficacy. The patent emphasizes how DVP affects GHB’s pharmacokinetics, allowing adjustments to minimize side effects while ensuring therapeutic benefits.
The role of CELLETS® in this patent is critical. CELLETS® are microcrystalline cellulose spheres used in drug formulations. They provide a stable, controlled-release matrix for GHB, ensuring consistent drug delivery over time. This controlled release minimizes fluctuations in drug concentrations, improving safety and efficacy. These MCC starter beads also help prevent interaction between GHB and DVP, ensuring that neither drug’s therapeutic effects are compromised.
By using CELLETS®, the formulation enhances the pharmacokinetic profile of GHB, ensuring a smoother and more predictable drug release. This innovation is crucial when GHB is administered alongside DVP, as it allows for better management of conditions like excessive daytime sleepiness or cataplexy, without significantly altering either drug’s profile.
In summary, this patent introduces an optimized co-administration strategy for GHB and DVP, with Cellets playing a pivotal role in achieving steady, controlled drug release and mitigating adverse drug interactions. This approach aims to improve the overall effectiveness and safety of treatment for sleep-related disorders. In this specific patent, the following MCC Sphere types are recommended: CELLETS® 90, CELLETS® 100 or CELLETS® 127. United States Patent Application US20240024263 seems as well to be a patent following the patent US11896572B2 wherein modified-release formulations are described.
Read more here
Product Information
| Product, standard sizes | Size |
|---|---|
| Cellets 100 | 100-200 µm |
| Cellets 200 | 200-355 µm |
| Cellets 350 | 350-500 µm |
| Cellets 500 | 500-710 µm |
| Cellets 700 | 700-1000 µm |
| Cellets 1000 | 1000-1400 µm |
Source: ingredientpharm, website Patent on methods of administering gamma-hydroxybutyrate compositions with divalproex sodium, https://cellets.com/portfolio-item/cellets/
You might also like:
- Patent on extended release compositions comprising pyridostigmine
- Patent on extended-release compositions comprising atomoxetine
